261 related articles for article (PubMed ID: 24582381)
1. The role of evidence and the expert in contemporary processes of governance: the case of opioid substitution treatment policy in England.
Duke K; Thom B
Int J Drug Policy; 2014 Sep; 25(5):964-71. PubMed ID: 24582381
[TBL] [Abstract][Full Text] [Related]
2. Substitution treatment in the era of "recovery": An analysis of stakeholder roles and policy windows in Britain.
Duke K; Herring R; Thickett A; Thom B
Subst Use Misuse; 2013 Aug; 48(11):966-76. PubMed ID: 23952509
[TBL] [Abstract][Full Text] [Related]
3. Stakeholders' role in contemporary "substitute drug" prescribing policies in Italy.
Beccaria F; Rolando S
Subst Use Misuse; 2013 Aug; 48(11):943-53. PubMed ID: 23952507
[TBL] [Abstract][Full Text] [Related]
4. Shifts in opioid substitution treatment policy in Denmark from 2000-2011.
Frank VA; Bjerge B; Houborg E
Subst Use Misuse; 2013 Aug; 48(11):997-1009. PubMed ID: 23952511
[TBL] [Abstract][Full Text] [Related]
5. Stakeholders in opioid substitution treatment policy: similarities and differences in six European countries.
Thom B; Duke K; Frank VA; Bjerge B
Subst Use Misuse; 2013 Aug; 48(11):933-42. PubMed ID: 23952506
[TBL] [Abstract][Full Text] [Related]
6. 'Naloxone works': The politics of knowledge in 'evidence-based' drug policy.
Lancaster K; Treloar C; Ritter A
Health (London); 2017 May; 21(3):278-294. PubMed ID: 28135864
[TBL] [Abstract][Full Text] [Related]
7. Governance versus government: drug consumption rooms in Australia and the UK.
Zampini GF
Int J Drug Policy; 2014 Sep; 25(5):978-84. PubMed ID: 24746642
[TBL] [Abstract][Full Text] [Related]
8. The science and practice of medication-assisted treatments for opioid dependence.
Pecoraro A; Ma M; Woody GE
Subst Use Misuse; 2012; 47(8-9):1026-40. PubMed ID: 22676570
[TBL] [Abstract][Full Text] [Related]
9. European micronutrient recommendations aligned: a general framework developed by EURRECA.
Dhonukshe-Rutten RA; Timotijevic L; Cavelaars AE; Raats MM; de Wit LS; Doets EL; Tabacchi G; Roman B; Ngo-de la Cruz J; Gurinovic M; de Groot LC; van 't Veer P
Eur J Clin Nutr; 2010 Jun; 64 Suppl 2():S2-10. PubMed ID: 20517317
[TBL] [Abstract][Full Text] [Related]
10. Drug consumption rooms and the role of politics and governance in policy processes.
Houborg E; Frank VA
Int J Drug Policy; 2014 Sep; 25(5):972-7. PubMed ID: 24572642
[TBL] [Abstract][Full Text] [Related]
11. Commentary on "Substitution treatment in the era of 'recovery': an analysis of stakeholder roles and policy windows in Britain".
Neale J
Subst Use Misuse; 2013 Aug; 48(11):1059-60. PubMed ID: 23952515
[No Abstract] [Full Text] [Related]
12. Power relations and contrasting conceptions of evidence in patient-involvement processes used to inform health funding decisions in Australia.
Lopes E; Carter D; Street J
Soc Sci Med; 2015 Jun; 135():84-91. PubMed ID: 25950114
[TBL] [Abstract][Full Text] [Related]
13. Behind the scenes: the justifications for opioid maintenance treatment in Finland.
Perälä R; Hellman M; Leppo A
Subst Use Misuse; 2013 Aug; 48(11):954-65. PubMed ID: 23952508
[TBL] [Abstract][Full Text] [Related]
14. Walking through mud; history of the Polish methadone maintenance treatment from its stakeholders' perspective.
Moskalewicz J; Welbel M
Subst Use Misuse; 2013 Aug; 48(11):977-96. PubMed ID: 23952510
[TBL] [Abstract][Full Text] [Related]
15. Social construction and the evidence-based drug policy endeavour.
Lancaster K
Int J Drug Policy; 2014 Sep; 25(5):948-51. PubMed ID: 24491356
[TBL] [Abstract][Full Text] [Related]
16. Making drug policy together: reflections on evidence, engagement and participation.
Roberts M
Int J Drug Policy; 2014 Sep; 25(5):952-6. PubMed ID: 24882708
[TBL] [Abstract][Full Text] [Related]
17. What is good governance in the context of drug policy?
Singleton N; Rubin J
Int J Drug Policy; 2014 Sep; 25(5):935-41. PubMed ID: 24768218
[TBL] [Abstract][Full Text] [Related]
18. Intelligent policy making? Key actors' perspectives on the development and implementation of an early years' initiative in Scotland's public health arena.
Deas L; Mattu L; Gnich W
Soc Sci Med; 2013 Nov; 96():1-8. PubMed ID: 24034945
[TBL] [Abstract][Full Text] [Related]
19. Deviance or innovation? Recent changes of drug substitution treatment policy in Austria.
Eisenbach-Stangl I
Subst Use Misuse; 2013 Aug; 48(11):1010-21. PubMed ID: 23952512
[TBL] [Abstract][Full Text] [Related]
20. Drug Policy Governance in the UK: lessons from changes to and debates concerning the classification of cannabis under the 1971 Misuse of Drugs Act.
Monaghan M
Int J Drug Policy; 2014 Sep; 25(5):1025-30. PubMed ID: 24635973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
